Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 18, 2026, 2:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 30 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Sevelamer carbonate Clear all
Completed Phase 3 Interventional Results available

Head to Head Study Against Sevelamer Hydrochloride

NCT00441545
View directory record Official record
Conditions
Chronic Kidney Disease, Stage 5
Interventions
Fosrenol (Lanthanum Carbonate), Sevelamer hydrochloride
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
34
States / cities
Mesa, Arizona • Phoenix, Arizona • Tempe, Arizona + 29 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Sep 18, 2026, 2:38 PM EDT
Completed Phase 4 Interventional Results available

A Long-Term Study of Tenapanor Alone or in Combination With Sevelamer in Patients With CKD on Dialysis and HP

NCT03988920
View directory record Official record
Conditions
Hyperphosphatemia, End Stage Renal Disease
Interventions
Tenapanor, Sevelamer Carbonate
Drug
Lead sponsor
Ardelyx
Industry
Eligibility
Not listed
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Houston, California
Source: ClinicalTrials.gov public record
Updated Mar 28, 2023 · Synced Sep 18, 2026, 2:38 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Sevelamer and Secondary Hyperparathyroidism in Chronic Kidney Disease

NCT01191762
View directory record Official record
Conditions
Hyperparathyroidism, Chronic Kidney Disease
Interventions
sevelamer carbonate, placebo
Drug
Lead sponsor
Kenneth R. Phelps, M.D.
Individual
Eligibility
18 Years to 120 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Oct 31, 2016 · Synced Sep 18, 2026, 2:38 PM EDT
Completed Phase 2 Interventional Results available

An Efficacy and Safety Study of Sevelamer Carbonate in Hyperphosphatemic Pediatric Participants With Chronic Kidney Disease

NCT01574326
View directory record Official record
Conditions
Hyperphosphatemia, Chronic Kidney Disease
Interventions
Placebo, Sevelamer carbonate
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
Up to 18 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
23
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2016 · Synced Sep 18, 2026, 2:38 PM EDT
Completed Phase 2 Interventional

Cross-Over Study of Sevelamer Hydrochloride and Sevelamer Carbonate

NCT00440648
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
sevelamer carbonate, sevelamer hydrochloride, sevelamer hydrochloride, sevelamer carbonate
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
15
States / cities
Mobile, Alabama • Riverside, California • Greenwood Village, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2014 · Synced Sep 18, 2026, 2:38 PM EDT
Completed Phase 2 Interventional Results available

Sevelamer for Reducing Endotoxemia and Immune Activation

NCT01543958
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Sevelamer carbonate, Sevelamer carbonate
Drug · Device
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
15
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2018 · Synced Sep 18, 2026, 2:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Comparing Absorption of Dietary Phosphorus When Administering FOSRENOL® or RENVELA® in Healthy Adult Volunteers

NCT00875017
View directory record Official record
Conditions
Kidney Failure, Chronic
Interventions
Lanthanum Carbonate, Sevelamer
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 45 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Sep 18, 2026, 2:38 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

NCT04278404
View directory record Official record
Conditions
Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Hemophilia, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome
Interventions
The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
Drug
Lead sponsor
Duke University
Other
Eligibility
0 Years to 20 Years
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
49
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 40 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 18, 2026, 2:38 PM EDT
Terminated Phase 4 Interventional

Effect of Phosphate Binders on Markers of Vascular Health in Chronic Kidney Disease Stages 3 and 4

NCT01277497
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Sevelamer carbonate, Calcium acetate
Drug
Lead sponsor
Albany College of Pharmacy and Health Sciences
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Jan 13, 2016 · Synced Sep 18, 2026, 2:38 PM EDT
Completed No phase listed Observational

Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

NCT01431326
View directory record Official record
Conditions
Adenovirus, Anesthesia, Anxiety, Anxiolysis, Autism, Autistic Disorder, Bacterial Meningitis, Bacterial Septicemia, Benzodiazepine, Bipolar Disorder, Bone and Joint Infections, Central Nervous System Infections, Convulsions, Cytomegalovirus Retinitis, Early-onset Schizophrenia Spectrum Disorders, Epilepsy, General Anesthesia, Gynecologic Infections, Herpes Simplex Virus, Infantile Hemangioma, Infection, Inflammation, Inflammatory Conditions, Intra-abdominal Infections, Lower Respiratory Tract Infections, Migraines, Pain, Pneumonia, Schizophrenia, Sedation, Seizures, Skeletal Muscle Spasms, Skin and Skin-structure Infections, Treatment-resistant Schizophrenia, Urinary Tract Infections, Withdrawal, Sepsis, Gram-negative Infection, Bradycardia, Cardiac Arrest, Cardiac Arrhythmia, Staphylococcal Infections, Nosocomial Pneumonia, Neuromuscular Blockade, Methicillin Resistant Staphylococcus Aureus, Endocarditis, Neutropenia, Headache, Fibrinolytic Bleeding, Pulmonary Arterial Hypertension, CMV Retinitis, Hypertension, Chronic Kidney Diseases, Hyperaldosteronism, Hypokalemia, Heart Failure, Hemophilia, Heavy Menstrual Bleeding, Insomnia
Interventions
The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
Drug
Lead sponsor
Daniel Benjamin
Other
Eligibility
Up to 21 Years
Enrollment
3,520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
43
States / cities
Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2023 · Synced Sep 18, 2026, 2:38 PM EDT
Completed Phase 3 Interventional

Study to Compare Sevelamer Carbonate Powder to Sevelamer Hydrochloride Tablets in Patients With CKD on Hemodialysis

NCT00268957
View directory record Official record
Conditions
Kidney Diseases, Chronic Renal Insufficiency, End-Stage Renal Disease
Interventions
Sevelamer carbonate (Renvela®), Sevelamer hydrochloride (Renagel®)
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
29
States / cities
Birmingham, Alabama • Gadsden, Alabama • Mission Hills, California + 26 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2014 · Synced Sep 18, 2026, 2:38 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study to Investigate the Safety and Efficacy of PA21, a Phosphate Binder, in Dialysis Patients

NCT01324128
View directory record Official record
Conditions
Chronic Kidney Disease Requiring Chronic Dialysis
Interventions
PA21 (2.5 g tablet containing 500 mg iron), Sevelamer carbonate, PA21-1 (1.25 g tablet containing 250 mg iron)
Drug
Lead sponsor
Vifor Pharma
Industry
Eligibility
18 Years and older
Enrollment
1,059 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 23, 2014 · Synced Sep 18, 2026, 2:38 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Drug-drug Interaction Study of TPOXX When Co-administered With Phosphate Binders

NCT04485039
View directory record Official record
Conditions
Smallpox
Interventions
Tecovirimat, sevelamer carbonate oral tablet, sucroferric oxyhydroxide chewable tablet, calcium acetate oral tablet, Lanthanum Carbonate Chewable Tablet
Drug
Lead sponsor
SIGA Technologies
Industry
Eligibility
18 Years to 50 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 18, 2026, 2:38 PM EDT
Not listed Phase 4 Interventional

How Bone is Made in Children Receiving Dialysis

NCT01799317
View directory record Official record
Conditions
Bone Mineralization Defect
Interventions
Vitamin D2
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
6 Years to 21 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
2
States / cities
Loma Linda, California • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 25, 2013 · Synced Sep 18, 2026, 2:38 PM EDT
Completed Phase 2 Interventional Results available

Randomized Study Comparing Genz-644470, Placebo, and Sevelamer Carbonate in Chronic Kidney Disease Patients on Hemodialysis

NCT00853242
View directory record Official record
Conditions
Kidney Failure, Chronic
Interventions
Placebo, Genz-644470, Sevelamer carbonate
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
349 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
52
States / cities
Alexander City, Alabama • Birmingham, Alabama • Hot Springs, Arkansas + 49 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Sep 18, 2026, 2:38 PM EDT
Terminated Not applicable Interventional Results available

The Effect(s) of Sevelamer Carbonate (Renvela) on Atherosclerotic Plaque Inflammation Judged by FDG-PET Scan

NCT01238588
View directory record Official record
Conditions
Dialysis, Cardiovascular Disease, Atherosclerosis, Inflammation, Hyperphosphatemia
Interventions
Sevelamer Carbonate (Renvela)
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
50 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
10
States / cities
Boston, Massachusetts • Framingham, Massachusetts • Marlborough, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2017 · Synced Sep 18, 2026, 2:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Examine the Effect of Renvela on the Pharmacodynamics of AZD1722

NCT02346890
View directory record Official record
Conditions
Healthy
Interventions
AZD1722, Renvela
Drug
Lead sponsor
Ardelyx
Industry
Eligibility
19 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 26, 2015 · Synced Sep 18, 2026, 2:38 PM EDT
Completed Early Phase 1 Interventional

Effects of a Non-Calcium Based Phosphate Binder on FGF23 Levels in Chronic Kidney Disease

NCT01308242
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Sevelamer Carbonate
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 1, 2018 · Synced Sep 18, 2026, 2:38 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Extension Study to Investigate the Long-term Safety, Tolerability and Efficacy of PA21, a Phosphate Binder in Dialysis Patients

NCT01464190
View directory record Official record
Conditions
Chronic Kidney Disease Requiring Chronic Dialysis
Interventions
PA21 (2.5 g tablet containing 500 mg iron), Sevelamer carbonate
Drug
Lead sponsor
Vifor Pharma
Industry
Eligibility
18 Years and older
Enrollment
659 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 31, 2014 · Synced Sep 18, 2026, 2:38 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Study to Evaluate the Efficacy of Tenapanor as Adjunctive Therapy to Phosphate Binder Therapy

NCT03824587
View directory record Official record
Conditions
Hyperphosphatemia
Interventions
Tenapanor, Placebo, Phosphate Binder Agents
Drug
Lead sponsor
Ardelyx
Industry
Eligibility
18 Years to 80 Years
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
48
States / cities
Huntsville, Alabama • Pine Bluff, Arkansas • Beverly Hills, California + 41 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2023 · Synced Sep 18, 2026, 2:38 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study of Tenapanor to Treat Hyperphosphatemia in ESRD Patients on Dialysis

NCT03427125
View directory record Official record
Conditions
Hyperphosphatemia
Interventions
Tenapanor, Placebo, Sevelamer Carbonate
Drug
Lead sponsor
Ardelyx
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,559 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
The Bronx, New York • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Sep 18, 2026, 2:38 PM EDT
Completed Not applicable Interventional Results available

A Double Blind Randomized Placebo Trial of Maintenance of Normal Serum Phosphorus in CKD

NCT00785629
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Calcium acetate, Lanthanum Carbonate, Sevelamer Carbonate, Placebo
Drug
Lead sponsor
Denver Nephrologists, P.C.
Other
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 29, 2012 · Synced Sep 18, 2026, 2:38 PM EDT
Completed Phase 1 Interventional

A Phase1 Study to Explore the Safety of EOS789 in Patients With Chronic Kidney Disease and Hyperphosphatemia on Hemodialysis

NCT02965053
View directory record Official record
Conditions
Hyperphosphatemia
Interventions
EOS789, Placebo, Renvela
Drug
Lead sponsor
Chugai Pharmaceutical
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 12, 2018 · Synced Sep 18, 2026, 2:38 PM EDT
Completed Phase 2 Interventional

The Effects of Sevelamer Carbonate on Diabetic Nephropathy

NCT01493050
View directory record Official record
Conditions
Diabetic Nephropathy
Interventions
Sevelamer Carbonate, calcium carbonate
Drug
Lead sponsor
Gary Striker
Other
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 8, 2014 · Synced Sep 18, 2026, 2:38 PM EDT